# Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

> **NCT03362073** · PHASE2 · UNKNOWN · sponsor: **Pusan National University Yangsan Hospital** · enrollment: 26 (estimated)

## Conditions studied

- Ketamine
- Refractory Cancer Pain

## Interventions

- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT03362073
- **Lead sponsor:** Pusan National University Yangsan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362073, "Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT03362073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*